



pipeline™ exclusive - Explosives detection software developer seeks \$10 million with a view to acquire

Guardian Technologies International, Inc. (OTCBB : GDTI), based in Herndon, VA, is a holding company with the exclusive rights to a next-generation imaging analysis technology capable of extracting, detecting and identifying objects-of-interest within digitised still and video images. Importantly, the software can operate irrespective of the image sensory source, be it digital, multi-spectral, hyper-spectral or infrared. The company plans to commercialise this technology through licensing the distribution rights to two wholly-owned subsidiaries, one targeting healthcare applications (which has already been established); and one targeted at the airport security market (which is soon to be formed).

Based on the core technology, a distinct product has been developed for each subsidiary. The first, PinPoint, is a post-image acquisition analysis solution designed to operate with commercial-off-the-shelf (“COTS”) radiographic and millimeter wave body and baggage scanners for the detection of explosive materials and threat items at airport and facility security checkpoints. The second product is called Signature Mapping TBDx, a healthcare solution designed to automatically identify and quantify tuberculosis bacilli via sputum microscopy. Based on machine learning technology, PinPoint’s core image analysis engine uses an iterative-transformational-process to reveal “unique signatures” of objects that cannot be discriminated and identified by the human eye. Unlike competing computer analysis solutions that compare densities and z-effective values of objects in x-ray images with known parameters of explosive materials, PinPoint requires no pre-existing knowledge of the object’s shape, volume, texture or specific density.

In June 2003 Guardian listed on the NASDAQ’s Over-The-Counter Bulletin Board (OTCBB) via a reverse takeover of a public shell entity. The company is effectively pre-revenue, generating revenues of c.\$73,000 in the nine-month period ending September 30th 2009, primarily from research funding. Speaking recently to VB/Research Bill Donovan, President of Guardian Technologies, explained that phase two clinical trials of Signature Mapping TBDx are due to be completed in late February, with commercial sales expected to start in April-May. The PinPoint technology has been trialled at numerous locations around the world. The company is closest to sales in India and South Africa. Revenues from both these activities are forecast to reach \$22 million in 2010, rising to \$100 million in 2011. The company currently has a market capitalisation of \$8.7 million.



To realise this growth, Donovan explained that Guardian Technologies is currently looking to raise \$10 million from institutional or high-net-worth individuals. The money will be used as working capital and to fund strategic acquisitions. Targets should be developing complementary technologies in the areas of imaging, scanner integration and data mining. Some of the proceeds will also be used to fund development of additional healthcare products, such as a breast cancer detection product based on the core Signature Mapping technology.

Please contact Julie Shepherd, at: julie@accentuatePR.com, for more information on Guardian Technologies International, Inc.

About VB/Research

VB/Research (www.vbresearch.com) has been providing sector intelligence, data and tailored research covering the Security (IT & Homeland) and Defense sector since 2005. Members of our service include governments, private and public corporations, investment banks, venture capitalists, private equity funds, hedge funds and law firms in over 55 countries. VB/Research was founded in 2005 and employs 20 analysts and journalists in various locations worldwide.